Bevacizumab is a humanized mAb blocking all isoforms of VEGF-A; several phase III trials demonstrated improved survival in combination with chemotherapy compared to chemotherapy alone in first-line and second-line settings, both in bevacizumab naive and pretreated patients, irrespective of tumor sidedness and RAS/BRAF mutational status [48,49,50]. The gene discussed is BRAF; the disease is neoplasm.